Abstract
Overview
Introduction
The treatment of menopausal symptoms is a common clinical challenge, with
vasomotor symptoms affecting an estimated 75% of women aged over 50 years.
Hormone replacement therapy (HRT) has formed the mainstay of treatment for
almost 60 years and is highly efficacious. However, concerns surrounding the
safety of HRT have led to an increase in demand for non-hormonal alternatives.
Scope
- Overview of menopause, including a review of the prevalence of vasomotor
symptoms to better understand the size of the target patient population.
- Summary of topical issues in the treatment of menopausal symptoms and
rationale for a non-hormonal approach treatment.
- Review of pipeline non-hormonal drugs and analysis of their future
potential in relation to currently available hormone replacement therapy.
- Insight from interviews with seven key international experts in the field
of menopause and associated treatments
Highlights
The key opportunity for non-hormonal treatments lies in capturing sales that
have been lost by the hormonal treatments since the WHI results. Despite
increased demand, the current R&D pipeline for non-hormonals is small and
lacks innovation. Wyeth' s Pristiq could be first to market although regulatory
delays indicate possible non-approval.
Returning confidence in HRT among gynecologists and the recent upturn in sales
of these therapies represents a growing barrier to entry for non-hormonal drug
companies. Nevertheless, prevailing mistrust of HRT among primary care
physicians (PCPs) and eligible patients represents a key market opportunity
for non-hormonals.
In view of the lower efficacy of non-hormonals compared to HRT, it is expected
that uptake will be strongest among patient groups for whom HRT is
contraindicated, as well as highly symptomatic patients who do not wish to
receive HRT due to safety concerns. Mildly symptomatic patients also represent
a key target group.
Reasons to Purchase
- Understand key opinion leaders views on topical issues in the current and
future treatment of menopausal symptoms.
- Explore the R&D pipeline for non-hormonals and the future directions of
the market as identified by interviewed KOLs.
- Identify the drivers and resistors for key non-hormonal drug treatments in
the market.
| 
View Cart
